Toripalimab

Toripalimab has received NCCN category 1 recommendation for nasopharyngeal carcinoma based on positive phase 3 data in both first-line and second-line settings, unlike pembrolizumab which showed negative results in the KEYNOTE-122 trial.

Oncologists identify delayed ENT referrals and non-specific respiratory symptoms as primary barriers to timely nasopharyngeal cancer diagnosis.

STORM Therapeutics has dosed the first patient in a Phase 1b/2 combination study evaluating STC-15, a METTL3 inhibitor, with LOQTORZI (toripalimab) for multiple cancer types.

• China's NMPA has approved Junshi Biosciences' IND application for JS212, a first-in-class bispecific antibody-drug conjugate simultaneously targeting EGFR and HER3 in various tumor types. • The dual-targeting mechanism of JS212 potentially offers advantages over traditional single-target ADCs, including broader efficacy across multiple cancers and reduced risk of drug resistance. • BioDlink, a global CDMO with specialized ADC expertise, provided comprehensive development and manufacturing support for the technically complex bispecific ADC candidate.

Antengene will present data from four preclinical studies at AACR 2025, featuring novel T-cell engagers and a synthetic lethality approach targeting MTAPnull cancers.